GEMITERO gemcitabine (as hydrochloride) 200 mg powder for injection vial

Land: Australien

Sprache: Englisch

Quelle: Department of Health (Therapeutic Goods Administration)

Wirkstoff:

gemcitabine hydrochloride, Quantity: 228 mg

Verfügbar ab:

Hetero Australia Pty Ltd

INN (Internationale Bezeichnung):

Gemcitabine hydrochloride

Darreichungsform:

Injection, powder for

Zusammensetzung:

Excipient Ingredients: mannitol; sodium hydroxide; sodium acetate trihydrate

Verabreichungsweg:

Intravenous Infusion

Einheiten im Paket:

1 vial

Verschreibungstyp:

(S4) Prescription Only Medicine

Anwendungsgebiete:

Gemcitabine is indicated for treatment of patients with locally advanced or metastatic non- small cell lung cancer.,Gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. Gemcitabine is also indicated for patients with 5-FU refractory pancreatic cancer.,Gemcitabine, alone or in combination with cisplatin, is indicated for treatment of patients with bladder cancer.,Gemcitabine, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicated.,Gemcitabine, in combination with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum? based therapy

Produktbesonderheiten:

Visual Identification: White to off-white lyophilised powder to be reconstituted for intravenous use.; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 2 Years; Container Temperature: Store below 25 degrees Celsius

Berechtigungsstatus:

Licence status A

Berechtigungsdatum:

2015-03-03